

IRL-1620**Cat. No.:** RP13497**Size:** 0.2 mg**Alias:** IRL-1620; IRL1620**Description:**

IRL-1620 significantly enhanced delivery and effectiveness of paclitaxel in an animal model of breast cancer. IRL-1620 together with IRL-1038 (Prod. No. ALX-155-007) is an indispensable pharmacological tool to assess the participation of the ETB receptor in some pathophysiological phenomena, by selectively stimulating ETB receptor-mediated responses in various pathophysiological models established in vitro and in vivo.

Cas No: 142569-99-1**Sequence (one-letter code):**Suc-[Glu9Ala11,15]-Endothelin-1(8-21)Suc-
DEEAVYFAHLDIIW**Sequence (three-letter code):**Suc-[Glu9Ala11,15]-Endothelin-1(8-21)Suc-Asp-Glu-Glu-Ala-
Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp**Solubility:** Insoluble in water. Dissolve the content with > pH 8.5 buffer.**Formula:** C₈₆H₁₁₇N₁₇O₂₇**Molecular Weight:** 1,820.95**Purity:** > 95%**Storage:**

Store at -20°C.

Note: This peptide is most potent and specific ligand for the ETB receptor (KiETA/KiETB 0 000) as judged by the Ki values for ETA (1.9 μM) and ETB (16 pM) receptors. IRL1620 (10⁻⁹-10⁻⁷ μM) induced contraction of the guinea pig tracheal with a comparable potency to those of ET-1 or ET-3.

*For Non-Clinical Research Use Only *

